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Introduction: GH-secreting pituitary adenomas can be hypo-, iso- or hyperintense on T2-weighted 
MRI sequences. We observed that GH-secreting adenomas differ in their presentation and response 
to somatostatin analogues (SSA) depending on their T2-intensities. We conducted the current 
multicenter study to validate these results in a large population of patients with acromegaly that 
received  SSA as primary monotherapy. 
Method: Acromegaly patients primarily treated with SSA for at least 3 months were included in the 
study. Hormonal, clinical and general MRI assessments were performed and the data were 
centralized.  In addition, ROI measurement of the adenoma, normal pituitary tissue and temporal 
grey matter was performed. A ratio between the adenoma ROI and that of the reference tissues was 
calculated in order to correct for inter-exam variations. 
Results: 106 acromegalic patients were included. Of these, 76 were T2-hypointense, 14 iso- and 16 
hyperintense at diagnosis. SSA treatment duration was similar in the 3 groups. T2-hypointense 
adenomas had a better response to SSA treatment. The response correlated with the calculated ratio 
of T2-intensity. The lower the T2-weighted intensity, the greater the decrease of random GH 
(p<0.0001, r2=0.49), IGF1%ULN (p=0.0003, r2=0.113) and adenoma volume (p<0.0001, r2=0.378).  
Conclusion: T2-weighted signal intensity of GH-secreting adenomas correlates with the response to 
SSA primary treatment in acromegaly. This information could help in initial management decisions, as 
the information is available at the baseline diagnosis.  Routine use of pituitary adenoma T2-weighted 
signal intensity on MRI could be useful in acromegaly assessment and management. Further studies 
are underway to explain the molecular mechanisms underlying the behavior of adenomas with 
different T2-weighted signal intensities.   
